MonoSolRx LLC Enters Into Licensing Agreement With Vestiq Pharmaceuticals for Zuplenz® Oral Soluble Film

WARREN, N.J., Jan. 16, 2013 (GLOBE NEWSWIRE) -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced that it has licensed Zuplenz® (ondansetron) to Vestiq Pharmaceuticals, a specialty pharmaceutical company focused on innovative therapeutic remedies within the supportive care markets. Zuplenz is an oral soluble film (OSF) for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement comprised an undisclosed upfront payment from Vestiq, as well as double digit royalty payments from sales of Zuplenz. Vestiq relaunched Zuplenz in the United States in the fourth quarter of 2012. The approval of Zuplenz by the U.S. Food and Drug Administration (FDA) makes it the first oral soluble lingual film product approved by the FDA as a prescription medication, based on MonoSol Rx's proprietary PharmFilm® technology.